Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olmesartan medoxomil + amlodipine besylate + rosuvastatin calcium
- Development stage
- Unknown
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
DWJ1621 (OlloMax) is a fixed-dose triple combination therapy developed by Daewoong Pharmaceutical for the simultaneous management of hypertension and dyslipidemia. The formulation combines three established small molecule agents: olmesartan medoxomil, an angiotensin II receptor antagonist (ARB); amlodipine besylate, a dihydropyridine calcium channel blocker (CCB); and rosuvastatin calcium, an HMG-CoA reductase inhibitor (statin). By integrating these three mechanisms of action into a single oral solid dosage form, DWJ1621 aims to simplify complex treatment regimens, thereby improving patient adherence and providing comprehensive cardiovascular risk reduction. It was approved by the South Korean Ministry of Food and Drug Safety (MFDS) in 2019.
- Brand names
- OlloMax
- Other names
- DWJ-1621DWJ1621DWJ 1621
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)LTCC (Voltage-gated calcium channel (L-type))AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on olmesartan medoxomil + amlodipine besylate + rosuvastatin calcium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olmesartan medoxomil + amlodipine besylate + rosuvastatin calcium.